A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma.

A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma.

Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma (DLBCL) is a common, aggressive and poorly chemoresponsive subtype of DLBCL, characterized by constitutive canonical NF-κB signaling. Inhibition of NF-κB signaling leads to apoptosis of ABC-DLBCL cell lines, suggesting targeted disruption of this...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Georges Habineza Ndikuyeze, Anita Gaurnier-Hausser, Reema Patel, Albert S Baldwin, Michael J May, Patrick Flood, Erika Krick, Kathleen J Propert, Nicola J Mason
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2014
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/4e5bee67ecdb4a43b058c8a7e1188110
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/4e5bee67ecdb4a43b058c8a7e1188110

Ejemplares similares